WP Advisors LLC Increases Stake in Pfizer Inc. (NYSE:PFE)

WP Advisors LLC grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 563.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 520,854 shares of the biopharmaceutical company's stock after purchasing an additional 442,360 shares during the quarter. Pfizer makes up approximately 4.6% of WP Advisors LLC's portfolio, making the stock its 5th largest holding. WP Advisors LLC's holdings in Pfizer were worth $13,818,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $26,000. Gladius Capital Management LP grew its stake in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 38,015 shares during the period. Sierra Ocean LLC acquired a new position in Pfizer in the 4th quarter valued at $34,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Pfizer during the 3rd quarter worth $35,000. Finally, Joseph Group Capital Management boosted its holdings in shares of Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock worth $36,000 after purchasing an additional 771 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 1.6 %

NYSE PFE traded up $0.42 on Friday, reaching $26.32. The company had a trading volume of 54,560,140 shares, compared to its average volume of 38,524,395. The firm has a market capitalization of $149.14 billion, a PE ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.64. The firm has a 50-day moving average of $26.28 and a 200-day moving average of $27.44. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the business earned $0.10 EPS. The business's revenue was up 24.7% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This is a boost from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. Pfizer's payout ratio is 121.99%.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

PFE has been the topic of several recent analyst reports. Bank of America reiterated a "neutral" rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. StockNews.com lowered shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. Guggenheim reiterated a "buy" rating and issued a $33.00 price target on shares of Pfizer in a report on Monday, February 10th. Finally, Evercore ISI upgraded Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.